## UNITED STATES SECURITIES AND EXCHANGE COMMISSION November 12, 2014

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

MabVax Therapeutics Holdings, Inc.

File No. 333-199005 - CF#31657

MabVax Therapeutics Holdings, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on September 29, 2014, as amended.

Based on representations by MabVax Therapeutics Holdings, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.26	through October 14, 2017
Exhibit 10.27	through October 14, 2017
Exhibit 10.28	through October 14, 2017
Exhibit 10.29	through October 14, 2017
Exhibit 10.30	through June 30, 2016

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary